Cinnarizine Dosing
Based on FDA labeling for meclizine (a related antihistamine with similar properties), cinnarizine is typically dosed at 25-75 mg three times daily for vertigo and vestibular disorders, with dose adjustments required for elderly patients and those with hepatic or renal impairment.
Standard Dosing Regimen
Starting Dose
- Adults: 25 mg three times daily, taken with meals to minimize gastrointestinal side effects 1
- Alternative regimen: 75 mg twice daily has been studied and shows accumulation due to the drug's 23.6-hour half-life 2
Titration and Maintenance
- The fixed combination of cinnarizine 20 mg plus dimenhydrinate 40 mg three times daily has demonstrated efficacy in reducing vertigo symptoms, with improvement noted at 15 days and further benefit at 60 days 1
- For Meniere's disease specifically, cinnarizine 75 mg twice daily (150 mg total daily dose) has been evaluated over 8-week treatment periods 3
Maximum Dose
- Standard maximum: 225 mg per day (75 mg three times daily)
- Doses up to 150 mg daily (75 mg twice daily) have been studied with acceptable safety profiles 2
Special Population Considerations
Elderly Patients
Dose selection should start at the low end of the dosing range 4. Key considerations include:
- Begin with 25 mg twice daily rather than three times daily
- The elderly have greater frequency of decreased hepatic, renal, and cardiac function 4
- Monitor closely for anticholinergic effects (dry mouth, constipation, urinary retention)
- Increased risk of falls and sedation
Hepatic Impairment
Cinnarizine should be administered with caution in hepatic impairment 4:
- Mild impairment: Start at 25 mg twice daily; monitor for increased systemic exposure
- Moderate impairment: Consider 25 mg once or twice daily initially
- Severe impairment (Child-Pugh C): Avoid use or use only if benefits clearly outweigh risks, as metabolism may be significantly impaired 4
- Hepatic impairment may result in increased systemic exposure due to reduced metabolism 4
Renal Impairment
Use with caution due to potential drug/metabolite accumulation 4:
- Mild to moderate impairment (CrCl 30-80 mL/min): Start at 25 mg twice daily
- Severe impairment (CrCl <30 mL/min): Consider 25 mg once daily or every other day
- Renal function generally declines with age, requiring additional caution in elderly patients 4
Important Clinical Considerations
Pharmacokinetic Properties
- Half-life: 23.6 hours, leading to accumulation with twice-daily dosing 2
- Accumulation factor: 2.79 at steady state with 75 mg twice daily 2
- Time to peak: 3 hours after oral administration 2
- Steady state is typically achieved after 5-7 days of regular dosing
Administration Recommendations
- Take with food to reduce gastrointestinal side effects (nausea, vomiting)
- Maintain consistent timing of doses for optimal therapeutic effect
- For vertigo management, therapy duration of 60 days shows progressive improvement 1
Common Pitfalls to Avoid
- Do not start at maximum doses in elderly or renally/hepatically impaired patients—this increases risk of sedation and falls
- Avoid combining with other CNS depressants without dose adjustment
- Monitor for gender-specific responses: females may show different therapeutic responses compared to males 1
- Do not abruptly discontinue after prolonged use; taper if needed
Monitoring Parameters
- Assess vertigo/dizziness severity at baseline, 15 days, and 60 days
- Monitor for sedation, particularly in first 2 weeks
- Check renal function periodically in elderly patients
- Evaluate for anticholinergic effects (urinary retention, constipation, dry mouth)